Showing results (381-390 of 412) with videos related to
Sort By:
Pageof 42
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|March 15, 2021
Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims DatabaseHasan Ahmad Hasan Albitar, Holly Van Houten, Lindsey R Sangaralingham, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.Leukemia Research|April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemiaFrancis Giles, Srdan Verstovsek, Stefan Faderl, et al.Frontiers in Oncology|July 1, 2022
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid NeoplasmsAndrew Ip, Alexandra Della Pia, Gee Youn Geeny Kim, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|August 23, 2021
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjectsDavide Ferrari, Nicola Clementi, Sestina Maria Spanò, et al.Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.Journal of Clinical Lipidology|June 19, 2025
Homozygous familial hypercholesterolemia in a high-consanguinity population: Insights from a Saudi cohortAfaf Alsagheir, Ismail A Abdullah, Mohammed Albitar, et al.Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.Lung|January 11, 2022
ICU and Hospital Outcomes in Patients with Hepatopulmonary Syndrome Undergoing Liver TransplantationCatarina Aragon Pinto, Vivek Iyer, Yahya A Almodallal, et al.The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.Pageof 42